TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors

@inproceedings{He2016TACC3OI,
  title={TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors},
  author={Jun-chuang He and Wei Yao and Jianming Wang and Peter Schemmer and Yan Yang and Yan Liu and Ya-wei Qian and Wei-peng Qi and Jian Zhang and Qi Shen and Tao Yang},
  booktitle={Oncotarget},
  year={2016}
}
Histone deacetylases (HDACs) have been implicated in multiple malignant tumors, and HDAC inhibitors (HDACIs) exert anti-cancer effects. However, the expression of HDACs and the anti-tumor mechanism of HDACIs in cholangiocarcinoma (CCA) have not yet been elucidated. In this study, we found that expression of HDACs 2, 3, and 8 were up-regulated in CCA tissues and those patients with high expression of HDAC2 and/or HDAC3 had a worse prognosis. In CCA cells, two HDACIs, trichostatin (TSA) and… CONTINUE READING
Highly Cited
This paper has 176 citations. REVIEW CITATIONS
7 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.

176 Citations

020040020172018
Citations per Year
Semantic Scholar estimates that this publication has 176 citations based on the available data.

See our FAQ for additional information.

Similar Papers

Loading similar papers…